Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: J Heart Lung Transplant. 2015 Oct 30;35(3):362–369. doi: 10.1016/j.healun.2015.10.028

Table 3. Observed Outcomes of Transplant Recipients by Age Group.

Variable No avail Age 18-59 No
avail
Age 60-69 No
avail
Age 70+
Follow Up Outcomes
Length of Stay Transplant to Discharge, Median (25th, 75th) 1 17,229 14 (10, 21) 7,764 15 (10, 23) 555 15 (10, 23)
Treated for Rejection within 1 year, No (%) 16,905 6,464 (38.2) 7,151 2,106 (29.5) 427 76 (17.8)
Rehospitalizations in the First Year, No (%) 2 14,558 5,869 298
 2 25 (0.2) 14 (0.2) 1 (0.3)
 1 5,969 (41.0) 2,292 (39.1) 111 (37.3)
 0 8,564 (58.8) 3,563 (60.7) 186 (62.4)
If Renal Dysfunction, Chronic Dialysis at 1 year, No (%) 2 3,149 97 (3.1) 1,501 33 (2.2) 78 1 (1.3)
If Renal Dysfunction, Chronic Dialysis at 5 years, No (%) 3 2,311 182 (7.9) 939 51 (5.4) 35 6 (17.1)
Stroke at 1 year, No (%) 2 9,445 95 (1.0) 3,369 38 (1.1) 124 3 (2.4)
Stroke at 5 year, No (%) 3 6,257 66 (1.1) 2,005 31 (1.5) 61 0
Post-Transplant Lymphoproliferative Disease at 1 Year, No (%) 2 187 33 (17.7) 211 10 (4.7) 18 2 (11.1)
Post-Transplant Lymphoproliferative Disease at 5 Years, No (%) 3 355 18 (5.1) 265 9 (3.4) 11 0
1

Excludes patients listed before Oct 25, 1999

2

Among patients alive at 1 year

3

Among patients alive at 5 years